Restructuring

9 Months Ended

Sep. 30, 2011

7. Restructuring

As part of the reorientation of our research and development focus on oncology, in the third quarter we reduced headcount resulting in a restructuring accrual of $1.1 million which will be paid during the period from October 2011 through August 2012. This accrual consists of:

	For the Three and Nine Months Ended September 30, 2011
Severance and related benefits	$	1,064
Total	$	1,064

Activity in the third quarter restructuring accrual, which is included in accounts payable and accrued expenses in our Consolidated Balance Sheets and research and development and general and administrative expenses in the Consolidated Statements of Operations, is specified below. We expect to incur additional employee termination benefit expense accruals related to this restructuring upon completion of arrangements finalized after third-quarter end.

	Severance and related benefits
Initial expense accrual	$	1,064
Cash payments		-
Balance at September 30, 2011	$	1,064